Can we make CAR-T cells last longer in leukemia?

NCT ID NCT05809284

First seen Aug 07, 2026 ยท Last updated Aug 07, 2026

Summary

This study follows children and young adults with acute lymphoblastic leukemia (ALL) who receive CAR-T cell therapy. The goal is to track how long these engineered immune cells persist in the body and identify factors that cause them to disappear. By understanding why CAR-T cells fade, researchers hope to improve the durability of this treatment.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
CD19-targeted CAR-T cell therapy (tisagenlecleucel)
What this could lead to
If successful, this could reveal why CAR-T cells stop working in some patients, potentially leading to longer-lasting remissions or improved treatments for ALL.
What could go wrong
This is an observational study, so it won't test a new treatment. It may not identify all factors affecting CAR-T persistence, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA NOT HAVING ACHIEVED REMISSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Great Ormond Street Hospital

    RECRUITING

    London, United Kingdom

  • Royal Manchester Children's Hospital

    RECRUITING

    Manchester, United Kingdom

  • University College London Hospital

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.